PALI Research and Charts

PALI - Palisade Bio Inc (Healthcare: Biotechnology)

Projected Earnings Date: 2024-08-13 (Delayed quote data 2025-05-09)

Last 0.75	Change ⇓ -0.01 (0.00%)	Volume 23,595
	Open 0.76	High 0.79	Low 0.74

8EMA (Daily) 0.77	40EMA (Daily) 0.80	50EMA (Daily) 0.85	STO (Daily) 74.853	MACD Hist (Daily) 0.021
8EMA (Weekly) 0.793	40EMA (Weekly) 1.77	50EMA (Weekly) 2.13	STO (Weekly) 13.048	MACD Hist (Weekly) 0.087


Company Profile
Palisade Bio Inc is a late-stage biopharma company. It is advancing oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio's innovative lead asset, LB1148, is a Phase 3-ready protease inhibitor with the potential to both reduce abdominal adhesions and help restore bowel function following surgery.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.